InspireMD Reports First Quarter Financial Results
MIAMI, InspireMD, Inc. (Nasdaq: NSPR), a leader in carotid artery disease treatment and stroke prevention through its innovative CGuard™ Prime carotid stent system, recently announced its financial and operational results for the first quarter.
Key Business Highlights
During this reporting period, InspireMD displayed significant advancements in its business initiatives. The company has been actively engaging with the U.S. Food and Drug Administration (FDA) regarding the Premarket Approval (PMA) application for its CGuard Prime carotid stent system, expressing optimism for an expected approval in the near term.
Furthermore, the company has strategically enhanced its commercial infrastructure and operational readiness, demonstrating renewed commitment to a successful U.S. launch. InspireMD has also seen robust enrollment in the CGUARDIANS II pivotal study, which evaluates the performance of the CGuard Prime stent during transcarotid artery revascularization (TCAR) procedures.
CEO Marvin Slosman's Insights
Marvin Slosman, CEO of InspireMD, conveyed enthusiasm about the progress made in the first quarter, underscoring the company's efforts to drive adoption of its pioneering technology in the markets it serves. He emphasized that InspireMD has established a solid operational and strategic foundation that is crucial for achieving the upcoming transformational milestones. With a comprehensive roadmap for expansion and an unwavering focus on operational excellence, the company is well-positioned to execute effectively upon obtaining FDA PMA approval.
Financial Overview of the First Quarter
In terms of financial performance, InspireMD reported a total revenue increase of $18,000, representing a 1.2% growth, totaling $1,529,000 compared to $1,511,000 for the corresponding quarter in the previous year. This modest increase is attributed to the continued adoption of the CGuard technology, despite facing challenges with foreign exchange fluctuations and distributor inventory management.
Gross profit for this quarter remained stable at $292,000, reflecting no change from the prior year’s figure. However, total operating expenses surged to $11,752,000, marking a significant increase of $4,046,000 or 52.5% compared to $7,706,000 in the same quarter last year. This rise is primarily due to expanded salaries and share-based compensation associated with the growing sales force in anticipation of FDA approval.
Net Loss and Financial Position
The financial income, net for the first quarter registered at $294,000 representing a 23% decline from $382,000 in the previous year, largely as a result of diminished interest income from marketable securities. The net loss for the quarter was recorded at $11,166,000, or $0.22 per basic and diluted share, slightly up from a net loss of $7,032,000, or $0.21 per share in the prior year.
As of the end of the first quarter, the company reported cash and cash equivalents along with marketable securities totaling $26,086,000, down from $34,637,000 at the end of the previous year.
Upcoming Conference Call and Corporate Updates
InspireMD’s management is set to host a conference call to discuss the financial results and share updates on corporate developments at 8:30 am ET on the day following the announcement. This interactive call will allow investors and stakeholders to engage in a question-and-answer session.
About InspireMD, Inc.
InspireMD is committed to establishing its proprietary MicroNet® technology as a benchmark for carotid stenting, aiming to deliver exceptional acute results and long-term, stroke-free outcomes. As a publicly traded entity on Nasdaq, InspireMD continues to post valuable information for investors on its corporate website.
For more investor-related queries, Craig Shore, Chief Financial Officer, can be contacted at 888-776-6804 or via email at craigs@inspiremd.com. Webb Campbell from Gilmartin Group LLC is also available for inquiries at Webb@gilmartinir.com.
Frequently Asked Questions
What products does InspireMD focus on?
InspireMD specializes in carotid artery stenting technology, particularly the CGuard™ Prime stent system designed to prevent strokes.
What recent milestone has InspireMD achieved?
The company has made strides in engaging with the FDA for the Premarket Approval of its CGuard Prime stent system.
How did InspireMD's revenue change in the last quarter?
The company saw a modest revenue increase of 1.2%, totaling $1,529,000 compared to the previous year's quarter.
What are the expectations for the upcoming FDA approval?
InspireMD is optimistic about receiving FDA approval for CGuard Prime in the near future.
How can investors contact InspireMD for inquiries?
Investors can reach out to Craig Shore or Webb Campbell via their respective emails for queries related to corporate performance and investor relations.
